Roivant Sciences (ROIV) Non Operating Investment Income (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of Non Operating Investment Income data on file, last reported at $131.0 million in Q4 2025.

• Quarterly Non Operating Investment Income rose 209.71% year-over-year to $131.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $282.6 million (up 572.8% YoY) and the FY2026 annual result came in at $105.0 million, up 90.35% from the prior year.
• Non Operating Investment Income rose to $131.0 million in Q4 2025, from $128.5 million in the prior quarter.
• In the past five years, Non Operating Investment Income ranged from a high of $443.8 million in Q3 2021 to a low of -$63.9 million in Q4 2023.
• A 5-year average of $65.0 million and a median of -$7.6 million in 2023 frame the typical range for Non Operating Investment Income.
• Annual changes were most pronounced in 2021 — Non Operating Investment Income surged 426.42% — and 2025, when it slumped 225.61%.
• Tracing ROIV's Non Operating Investment Income over 5 years: stood at $443.8 million in 2021, then slumped by 112.01% to -$53.3 million in 2022, then dropped by 19.9% to -$63.9 million in 2023, then soared by 166.2% to $42.3 million in 2024, then surged by 209.71% to $131.0 million in 2025.
• The last three Non Operating Investment Income figures came in at $131.0 million (Q4 2025), $128.5 million (Q3 2025), and -$19.1 million (Q2 2025), per Business Quant data.